Crossject Société Anonyme develops needle-free injection systems.
+ 1 more risk
Worrying balance sheet with weak fundamentals.
Share Price & News
How has Crossject Société Anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 74C's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: 74C underperformed the German Medical Equipment industry which returned 10.7% over the past year.
Return vs Market: 74C exceeded the German Market which returned -13.1% over the past year.
Price Volatility Vs. Market
How volatile is Crossject Société Anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Crossject Société Anonyme undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 74C's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 74C's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 74C is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: 74C is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 74C's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 74C is overvalued based on its PB Ratio (15.8x) compared to the DE Medical Equipment industry average (4.7x).
How is Crossject Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Healthcare industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 74C's forecast earnings growth is above the savings rate (-0.4%).
Earnings vs Market: Insufficient data to determine if 74C's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 74C's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 74C's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 74C's Return on Equity is forecast to be high in 3 years time
How has Crossject Société Anonyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 74C is currently unprofitable.
Growing Profit Margin: 74C is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 74C is unprofitable, and losses have increased over the past 5 years at a rate of -16.7% per year.
Accelerating Growth: Unable to compare 74C's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 74C is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17%).
Return on Equity
High ROE: 74C has a negative Return on Equity (-238.02%), as it is currently unprofitable.
How is Crossject Société Anonyme's financial position?
Financial Position Analysis
Short Term Liabilities: 74C's short term assets (€11.8M) exceed its short term liabilities (€5.2M).
Long Term Liabilities: 74C's short term assets (€11.8M) do not cover its long term liabilities (€16.2M).
Debt to Equity History and Analysis
Debt Level: 74C's debt to equity ratio (280.1%) is considered high.
Reducing Debt: Insufficient data to determine if 74C's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 74C has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 74C has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Crossject Société Anonyme's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 74C's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 74C's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 74C's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 74C's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 74C's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Patrick Alexandre co-founded Crossject Société Anonyme (f/k/a, Crossject Medical Technology) in 2001 and has been its Chairman of the Executive Board since 2012 and serves as its Chief Executive Office ...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 98.4%.
Crossject Société Anonyme's company bio, employee growth, exchange listings and data sources
- Name: Crossject Société Anonyme
- Ticker: 74C
- Exchange: DB
- Founded: 1997
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: €42.770m
- Shares outstanding: 24.03m
- Website: https://www.crossject.com
Number of Employees
- Crossject Société Anonyme
- 6 Rue Pauline Kergomard
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALCJ||ENXTPA (Euronext Paris)||Yes||Common Stock||FR||EUR||Feb 2014|
|74C||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2014|
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/10 02:49|
|End of Day Share Price||2020/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.